What's Up in Canada, Eh? Focus on Canadian Cancer Surveillance Research

Recorded On: 11/07/2022

Overview
Speaker(s)

"Lifetime probability of developing and dying from cancer in Canada, 1997-2020"

Presenter: JiaQi Leon Liu, MPH

The lifetime probability of developing and dying from cancer in Canada has been used as a measure of the general cancer experience among Canadians. This talk will present the most up-to-date estimates on lifetime probability of developing cancer up and lifetime probability of dying of cancer for Canadians.

"Central Nervous System Tumours in Canada from 2008-2017: Incidence, Prevalence and Survival"

Presenter: Emily Walker, PhD

This talk will present the most recent. comprehensive data on the incidence and prevalence of primary central nervous system (CNS) tumours in Canada, as well as the survival experience of Canadians diagnosed with a CNS tumour.

"The CanREValue Collaboration: Experience generating real-world evidence using real-world data from across Canada"

Presenter: Caroline Muñoz, MSc

The Canadian Real-world Evidence for Value in Cancer (CanREValue) Collaboration was established in 2017 to develop a framework for the generation and use of real-world evidence (RWE) of cancer drugs to inform drug funding decisions. This presentation will describe a demonstration project exploring the capacity to generate RWE in nine Canadian provinces, using data from cancer registries, hospital and emergency department records, and insurance claims, to provide direct, generalizable evidence on cancer drug effectiveness, safety, and cost-effectiveness.

JaiQi Leon Liu, MPH

Analyst

Statistics Canada

Leon is an analyst with Statistics Canada working with the cancer and chronic conditions data analysis team. Having professional degrees in both immunology and biostatistics, Leon is dedicated to bringing forth the best health data analytics to the Canadian public. Prior to joining Statistics Canada, Leon worked with the Brain Tumor Registry of Canada for generating survival, prevalence, and incidence estimates on CNS tumors and brain metastases.

Emily Walker, PhD

Epidemiologist, Cancer Advanced Analytics

Cancer Research & Analytics at Cancer Care Alberta

Dr. Walker is an epidemiologist with Cancer Advanced Analytics, within Cancer Research & Analytics at Cancer Care Alberta, and an Adjunct Professor with the School of Public Health, University of Alberta. She completed her PhD in Medicine, specializing in Epidemiology and Biostatistics at the University of Alberta. Dr. Walker’s work includes routing surveillance and reporting activities, collaborations with clinicians on research investigating cancer treatments and outcomes, and linking clinical and administrative data to generate evidence to support health system planning. She has been involved with the brain tumour registry work since 2017.

Caroline Muñoz, MSc

Research Associate

Ontario Health

Caroline Muñoz is a research associate with the Pharmacoeconomics Research Unit for Ontario Health’s Provincial Drug Reimbursement Programs. She obtained a Master of Community Health and Epidemiology from Dalhousie University in 2020. Caroline is involved in conducting real-world evidence studies comparing the effectiveness, safety, and cost-effectiveness of provincially funded IV cancer drugs. She is a Core Team member with the CanREValue Collaboration, a pan-Canadian collaboration of regulators, health technology agencies, public drug plan payers, clinicians and academic researchers aimed at developing a framework for the generation and use of real-world evidence for cancer drug funding decisions. Caroline works with the CanREValue Collaboration Data Working Group exploring the availability and accessibility of real-world oncology data in each province and the potential health or economic outcomes that can be measured from available data sources.